Farkas Morva

Omixon

Omixon is a global transplantation diagnostic company with a mission to provide histocompatibility laboratories with innovative technologies to improve transplant outcomes. Omixon is headquartered in Budapest, Hungary, with operations in the United States, Brazil and the Netherlands serving more than 60 laboratories worldwide. Building on multidisciplinary competences in bioinformatics, software engineering, molecular biology and regulatory science, Omixon transforms molecular biology innovations into state-of-the-art products in transplant diagnostics. Omixon was the first to successfully introduce NGS-based HLA typing kit and software in 2014 by bringing Holotype HLA, an NGS-based HLA genotyping product, and HLA Twin software to market. Omixon Twin delivers the most accurate high-resolution HLA genotyping and is used in more than 60+ laboratories worldwide. Omixon was the first to release a high-resolution HLA genotyping product NanoTYPE HLA™ with less than 5 hours turnaround time on the Oxford Nanopore sequencing platform complemented by NanoTYPER™ analysis software. Omixon is the first to bring to market the first donor-derived cell-free DNA kit HoloGRAFT for laboratories with donor-informative genetic markers with primer and probe sequences that are absent in the patient genotype by design.